Undisclosed Rare Disease Therapy(ies)
Rare Diseases (Protein Supplementation)
Pre-clinicalActive
Key Facts
Indication
Rare Diseases (Protein Supplementation)
Phase
Pre-clinical
Status
Active
Company
About Ziphius Vaccines
Ziphius Vaccines is an emerging biotech developing a proprietary self-amplifying RNA (saRNA) platform coupled with in-house lipid nanoparticle (LNP) delivery systems. The company leverages this technology to create a pipeline targeting infectious diseases, rare diseases, and oncology, aiming for potent, durable effects at lower doses than conventional mRNA. As a private, pre-clinical stage company, Ziphius is building its scientific team and platform capabilities to position itself in the competitive next-generation RNA therapeutics space.
View full company profile